Ignite Creation Date:
2025-12-24 @ 1:05 PM
Ignite Modification Date:
2025-12-31 @ 6:24 AM
Study NCT ID:
NCT01099761
Status:
TERMINATED
Last Update Posted:
2022-10-13
First Post:
2010-04-02
Is NOT Gene Therapy:
True
Has Adverse Events:
True
Brief Title:
Study of ACE-031 in Subjects With Duchenne Muscular Dystrophy
Sponsor:
Acceleron Pharma, Inc., a wholly-owned subsidiary of Merck & Co., Inc., Rahway, NJ USA
Organization:
Key Dates - Follows AllAPIJSON File Order
Start Date:
2010-04
Start Date Type:
None
Primary Completion Date:
2011-06
Primary Completion Date Type:
ACTUAL
Completion Date:
2011-06
Completion Date Type:
ACTUAL
First Submit Date:
2010-04-02
First Submit QC Date:
None
Study First Post Date:
2010-04-08
Study First Post Date Type:
ESTIMATED
Results First Submit Date:
2016-05-10
Results First Submit QC Date:
None
Results First Post Date:
2016-10-14
Results First Post Date Type:
ESTIMATED
Results First Post QC Date:
None
Results First Post QC Date Type:
None
Disp First Submit Date:
None
Disp First Submit QC Date:
None
Disp First Post Date:
2013-02-04
Disp First Post Date Type:
ESTIMATED
Last Update Submit Date:
2022-09-14
Last Update Post Date:
2022-10-13
Last Update Post Date Type:
ACTUAL